Highlights H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Delayed Nasdaq Copenhagen Other stock markets 16:20:00 13/05/2026 BST			5-day change	1st Jan Change
41.38 ^DKK	-0.43%		-2.77%	-4.12%

05-13	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
05-13	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW

Highlights

05-13	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
05-12	H. Lundbeck A/S Raises Earning Guidance for Full Year of 2026	CI
05-12	H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-19	H. Lundbeck A/S Presents New Data At AAN2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (Eptinezumab)	CI
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-20	H Lundbeck: Markets need more proof of growth promise
03-18	H. Lundbeck A/S Approves Dividend for the Accounting Year 2025	CI
03-16	H. Lundbeck A/S Advances Parkinson's Research With New Phase 1b Data On Lu AF28996 And Presents Updates On Multiple System Atrophy Programs	CI
03-09	H. Lundbeck A/S Announces Last Patient Randomized in Phase 3 Mascot Trial	CI
02-12	H. Lundbeck A/S Announces Positive Phase IIb Top-Line Results with Bocunebart (Lu AG09222; Anti-PACAP mAb) in Migraine Prevention	CI
02-06	H Lundbeck: Weak 2026 outlook a turn-off for investors
02-04	H. Lundbeck A/S Proposes Dividend for 2025	CI
02-04	H. Lundbeck A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-30	H. Lundbeck A/S Announces Six-Month Data from the 12-Month, Real-World Infuse Study	CI
12-06	H. Lundbeck A/S Announces Positive Phase 2 Long-Term Data for Bexicaserin in Rare Childhood-Onet Epilepsies, at American Epilepsy Society Annual Meeting	CI
12-02	H. Lundbeck A/S Presents Comprehensive New Bexicaserin Dataset Epilepsies	CI
11-26	Lundbeck Will Not Raise Its Bid for Avadel	FW
11-19	Alkermes Raises Offer for Avadel to $22.50 Per Share	FW
11-18	H. Lundbeck A/S (CPSE:HLUN B) cancelled the acquisition of Avadel Pharmaceuticals plc.	CI
11-17	Avadel Pharmaceuticals Board Deems Lundbeck's Takeover Proposal Superior	FW
11-14	H Lundbeck lifts guidance again as migraine and depression drugs drive growth
11-14	H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc for $2.1 billion.	CI
11-14	Lundbeck Makes Bid for Irish Firm Avadel Pharmaceuticals	FW
11-14	Lundbeck's New Drug Application for Migraine Preventive Drug Accepted by Japanese Ministry	MT
11-14	H. Lundbeck A/S Announces the Acceptance of Its New Drug Application	CI